← Back to Home

Gilead to acquire oral IL-23 receptor inhibitor program for $1.275 billion, expanding inflammatory bowel disease pipeline

PepStar's HCXT-2001 remains in Phase 1 clinical development, but Gilead has agreed to pay a substantial upfront sum for global rights. The deal expands its oral anti-inflammatory drug pipeline, though whether patients will benefit awaits clinical evidence.

By SURL BioNews

An oral drug candidate whose efficacy in humans has yet to be established has secured a $1.275 billion acquisition commitment. Gilead Sciences announced on October 22 that it would acquire PepStar Therapeutics' IL-23 receptor inhibitor program, adding HCXT-2001, which remains in Phase 1 clinical development, to its portfolio and opening another avenue in its inflammatory bowel disease (IBD) research and development efforts.

Under the agreement, Gilead will obtain global rights to the program and pay $1.275 billion in cash upfront at closing, subject to customary adjustments. The transaction is expected to close in the fourth quarter of 2026, subject to closing conditions. The acquisition covers the drug development program, rather than PepStar as a whole.

HCXT-2001 is an oral macrocyclic peptide designed to block the interleukin-23 receptor (IL-23R), interfering with signaling associated with immune inflammation. IBD is a group of chronic diseases in which the immune system persistently causes inflammation in the digestive tract, and is a potential use Gilead is targeting. However, a plausible mechanism of action does not directly establish that this molecule can improve patients' conditions.

A public trial registry provides a more specific outline of its development. The Phase 1 study, numbered NCT07792928, is expected to enroll 40 healthy adults and uses a randomized, placebo-controlled design to evaluate the safety, tolerability, pharmacokinetics and immunogenicity of two tablet formulations of HCXT-2001 following a single dose. The registry lists Shanghai Peptidstar Therapeutics Limited as the sponsor and Emerald Clinical Trials Pty Ltd as the collaborator.

The study is intended to address early questions, including how long the drug remains in the body and whether it triggers anti-drug antibodies. It is not an efficacy trial in patients with IBD, nor can it establish the risks of long-term dosing. Gilead has also explicitly stated that HCXT-2001's safety and efficacy have not been established and that it has not been approved by any regulatory authority.

The gap between the substantial payment and the early evidence has also become a focus of the deal. Reuters cited Citi analyst Geoffrey Meacham as noting that HCXT-2001 remains in early testing, with no published clinical data, making the $1.275 billion upfront payment particularly striking. For Gilead, the investment buys an opportunity for future development, along with the risk of clinical failure.

Gilead said it may develop HCXT-2001 on its own or in combination with other drug candidates in its portfolio. This leaves several possibilities for the new program within its development portfolio, but the benefits and risks of combination therapy also require testing. As development moves from early testing in healthy adults toward treatment for bowel disease, the next key question remains whether reproducible evidence of efficacy and safety can be established in patients.

References

  1. Gilead Sciences
  2. Reuters via SRN News
  3. ICH GCP clinical-trial registry mirror